We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EBMT:NASDAQEagle Bancorp Montana, Inc. Analysis

Data as of 2026-03-30 - not real-time

$20.29

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Eagle Bancorp Montana trades at $20.29, far below its DCF fair value of $65.29, implying a potential upside of over 8% and an undervalued position. The stock’s P/E of 10.68 is well under the industry average of 16.18, while the price‑to‑book of 0.83 suggests a discount to net asset value. Revenue grew 13.4% year‑over‑year and earnings per share reached $1.90 for 2025, with a quarterly dividend of $0.145 delivering a 2.86% yield and a modest 30% payout ratio, indicating dividend sustainability. Technical indicators show the 20‑day SMA (20.89) just above the current price, RSI at 39 points to mild oversold conditions, and a bearish MACD histogram, while volume is increasing and price sits near a $20 support level with $22.55 resistance. The stock’s beta of ~0.58 and 30‑day volatility of 23.8% reflect moderate market sensitivity, and the regional‑bank sector carries medium regulatory exposure.
Given the strong cash position, low leverage, and attractive yield, the upside potential from valuation gaps outweighs the near‑term technical weakness. The combination of solid earnings, disciplined dividend policy, and a defensive geographic footprint supports a buy stance across horizons, though investors should monitor macro‑economic pressures on regional banks and the upcoming earnings cycle.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Price near support with upside potential
  • Oversold RSI indicating possible rebound
  • Increasing volume supporting demand

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Valuation gap of >8% versus DCF fair value
  • Sustainable dividend yield and low payout ratio
  • Steady revenue growth and solid earnings

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Fundamentally sound balance sheet with ample cash
  • Regional focus limiting geographic concentration risk
  • Long‑term undervaluation relative to peers

Key Metrics & Analysis

Financial Health

Revenue Growth13.40%
Profit Margin16.41%
P/E Ratio10.7
ROE8.09%
ROA0.70%
P/B Ratio0.8
Op. Cash Flow$33.1M
Industry P/E16.2

Technical Analysis

TrendNeutral
RSI39.5
Support$20.00
Resistance$22.55
MA 20$20.89
MA 50$21.61
MA 200$18.37
MACDBearish
VolumeIncreasing
Fear & Greed Index67.96

Valuation

Fair Value$65.29
Target Price$22.00
Upside/Downside8.43%
GradeUndervalued
TypeBlend
Dividend Yield2.86%

Risk Assessment

Beta0.58
Volatility23.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.